{"groups":[{"description":"Subjects receive daily dose of 420 mg of Ibrutinib capsules","id":"FG000","title":"Phase 1b/Phase 2"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"5"}],"type":"cGVHD Progression"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Malignancy Progression/relapse"},{"reasons":[{"groupId":"FG000","numSubjects":"15"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"7"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"4"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"7"}],"type":"Study Terminated by Sponsor"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Noncompliance with study drug"}],"milestones":[{"achievements":[{"comment":"Phase 1b: 6 patients, 420 mg, no DLT observed. Phase 2: 42 patients, 420 mg","groupId":"FG000","numSubjects":"42"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"42"}],"type":"All-Treated Population"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"42"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}